UCLA Health’s menopause education refers to FDA-approved hormone therapy and discusses bioidentical and synthetic descriptions. The wording is more specific about a regulatory category than it is about the exact progesterone medicine a patient might be offered. Its clinical program is documented separately.
This review was completed September 29, 2026. It assesses those public descriptions without turning an educational recommendation into a verified UCLA capsule offer. No prescription, package or pharmacy transaction has been examined, and no conclusion about an individual’s treatment follows from the terminology alone.
Read this article by section
The approval recommendation comes from an educational article
UCLA’s article about considering hormone therapy, dated December 18, 2025, recommends an FDA-approved category. It does not give a named micronized progesterone product, a manufacturer selection or a pharmacy arrangement for a patient in the clinical program. Those missing details should not be supplied from familiarity with commonly discussed medicines.
The Northwestern review examines a different regulatory term, off-label. Both expressions become useful only when tied to a specific drug and purpose. Here, a recommendation about a category is not evidence that a particular item has been prescribed, that every future prescription follows one formula or that one preparation has demonstrated superior outcomes at UCLA.
Chemical identity and manufacturing are not opposing descriptions
The UCLA article discusses bioidentical and synthetic hormone descriptions. Those words should not be interpreted as a complete manufacturing history. The exact Prometrium label, used here as a separate product reference, describes progesterone made from plant-source starting material and chemically identical to ovarian progesterone.
That combination shows why manufactured and chemically identical are not mutually exclusive properties. It does not establish that UCLA prescribes Prometrium. The bioidentical approval guide addresses another separate property: regulatory status. A reader cannot determine a whole capsule’s ingredients, its approval record or personal suitability merely by choosing the most reassuring origin word in an educational discussion.
Use the FDA’s precise compounding distinction
The FDA explanation of compounded drugs identifies the absence of FDA approval and premarket review for safety, effectiveness and quality. That is a more precise regulatory statement than treating compounded as a synonym for having no rules at all. This review uses the FDA distinction when evaluating approval language.
It does not claim that UCLA supplies a compounded option or that the educational article is a product-level policy for every clinician. The question remains which preparation is actually proposed. Utah’s review explores institutional wording that separates conventional and compounded bioidentical options. These differences in explanation are not grounds for inventing a safety ranking among services.
A route list cannot establish matching evidence for progesterone
UCLA’s educational discussion lists several hormone-delivery forms. The presence of a form in a broad hormone article does not identify its active ingredient or prove that an unnamed progesterone product has equivalent evidence through another route. This review does not adopt a blanket equivalence conclusion from that menu.
Our oral, vaginal and topical guide explains why a preparation and its use need to be identified together. The micronized terminology page addresses a different descriptor and does not resolve route. No alteration in administration is proposed here. A general educational overview is not a basis for substituting products or transferring an ingredient list between forms.
The care program is broader than a medicine listing
UCLA’s clinical services page describes assessment across several aspects of midlife health. That establishes an actual menopause-care program. It does not make every area assessed an indication for progesterone or demonstrate that a particular medicine improves every outcome considered by the service.
This distinction matters because comprehensive care descriptions can look more decisive than they are about a drug. Assessment breadth and product specificity are different qualities of a public record. A clinician may discuss a concern without proposing a hormone for it. The review therefore separates what the program addresses from what is known about an eventual medicine, rather than presenting the scope of the clinic as evidence of a formulation’s benefits.
Visit information does not supply a dispensing schedule or full bill
The patient information page describes advance preparation and a comprehensive assessment process. Its annual assessment language is not a progesterone monitoring, refill or dispensing interval. Those medicine-specific arrangements are not established by the service’s visit description.
The reviewed pages also do not provide a selected patient’s complete cost covering the appointment, any additional assessment and a prescription. Regional clinical information does not establish unrestricted national access. Appointment conditions and financial responsibilities would need confirmation with the relevant service, followed by product-specific pharmacy information if a medicine is prescribed. No insurance determination, booking outcome or stock position was tested as part of this review.
The useful next detail is the item behind the category
The combination of UCLA’s clinical service and its educational article supports a review of a genuine provider’s language. It does not support a claim that UCLA sells a specific micronized capsule. The remaining identity question is substantive, even where a regulatory category has been clearly stated.
A product-specific explanation would name the preparation and distinguish its hormone, formulation, route and intended use. Evidence and warnings could then be considered for that actual item. Until that information is supplied, this assessment preserves the known service and the unknown medicine. It reports no firsthand treatment experience or clinical endorsement and does not turn a broad approval recommendation into an individual prescribing decision.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- UCLA Health — Considering menopausal hormone therapy?Institutional education dated December 18, 2025; used for its approval and identity terminology, not a formulary. Broad route-equivalence, low-dose and compounding-regulation claims are not adopted. · Checked 2026-09-29
- DailyMed — PROMETRIUM progesterone capsule, Acertis Pharmaceuticals LLCExact identified oral product labeling, updated July 23, 2026; text only, no package-image inspection. Ingredient, formulation and WHI study details are not assigned to a health-system prescription. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary explanation of absent FDA approval and premarket review, with risk-based oversight; not a claim that compounding is wholly unregulated or that any clinic uses it. · Checked 2026-09-29
- UCLA Health — Comprehensive Menopause Program: Clinical ServicesOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29
- UCLA Health — Comprehensive Menopause Program: Patient InformationOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29